C3 Glomerulopathy



Presentation



Proteinuria/ Microscopic hematuria




Retinal drusen



Histology



Mesangial proliferative, membranoproliferative, endocapillary proliferative pattern with or without crescents



Dominant C3 deposition ≥2 orders of magnitude over other immune reactants



<u>C3GN:</u> Amorphous mesangial ± subendothelial and subepithelial deposits

<u>DDD:</u>Dense osmiophilic mesangial and intramembranous deposits

Treatment



Optimal blood pressure control with ACE inhibitors/ARBs



Corticosteroids and mycophenolate mofetil in moderate to severe disease

Eculizumab doubtful role

Natural Course



30-50% of adults reach kidney failure within 10 years of diagnosis



Allograft failure within 10 years in 50% of recurrences



Histological recurrence as high as 90%

ACEi: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker; C3GN: C3 Glomerulonephritis; DDD: Dense Deposit Disease

 Goodship, Timothy H J et al. "Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "KDIGO Controversies Conference." *Kidney intl* vol. 91,3 (2017): 539-551. doi:10.1016/j.kint.2016.10.005
KDIGO Glomerular Diseases Work Group. "KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases." *Kidney intl* vol. 100,4S (2021): S1-S276. doi:10.1016/j.kint.2021.05.021 Created with BioRender.com

For funding and support information, see: https://www.theisn.org/ initiatives/toolkits/complement-mediated-kidney-disease-toolkit/#Support